This week, the overall grades of 11 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Insys Therapeutics, Inc. (INSY) gets weaker ratings this week as last week’s C drops to a D. Insys Therapeutics, Inc. develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company also gets F’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of INSY stock.

Clovis Oncology, Inc. (CLVS) declines this week from a D to a F. Clovis Oncology, Inc. is a biopharmaceutical company which focuses on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CLVS stock.

Trillium Therapeutics Inc.’s (TRIL) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TRIL stock.

Pfenex, Inc. (PFNX) slips from a C to a D this week. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of PFNX stock.

Proteon Therapeutics, Inc. (PRTO) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in earnings growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PRTO stock.

GlycoMimetics, Inc. (GLYC) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of GLYC stock.

This week, Aptose Biosciences Inc. (APTO) drops from a C to a D rating. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of APTO stock.

Slipping from a C to a D rating, Organovo Holdings, Inc. (ONVO) takes a hit this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ONVO stock.

Bio Blast Pharma Ltd. (ORPN) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ORPN stock.

This is a rough week for Curis, Inc. (CRIS). The company’s rating falls to D from the previous week’s C. Curis, Inc. is a drug discovery and development company that engages in the research and development of cancer therapeutics. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CRIS stock.

This week, BIND Therapeutics, Inc.’s (BIND) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in sales growth, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of BIND stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.